A review of mitotane in the management of adrenocortical cancer

Jaydira Del Rivero,Tobias Else,Julie Hallanger-Johnson,Katja Kiseljak-Vassiliades,Nitya Raj,Diane Reidy-Lagunes,Sandy Srinivas,Jill Gilbert,Anand Vaidya,Emily Aboujaoude,Irina Bancos,Antonio Tito Fojo

DOI: https://doi.org/10.1093/oncolo/oyae084

2024-09-06

Abstract:Importance: Mitotane (Lysodren, o,p'-DDD [1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane)] is currently the only United States Food and Drug Administration and European Medicines Agency-approved product for the treatment of adrenocortical carcinoma. Observations: Mitotane is challenging to administer; however, its toxicities (specifically adrenal insufficiency) are well known, and the management of adverse consequences has established approaches. While often viewed through the prism of a cytotoxic agent, it can also interfere with hormone production making it a valuable asset in managing functional ACC. A recently completed prospective trial has shed some light on its use in the adjuvant setting, but further clarity is needed. Many think mitotane has a role in the advanced or metastatic setting, although prospective data are lacking and retrospective analyses are often difficult to interpret. Conclusions and relevance: When used carefully and thoughtfully, especially in patients with hormonal excess, mitotane is an important component of the treatment armamentarium for ACC.